NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

Calidi Biotherapeutics, Inc. (CLDI) Stock Analysis

Calidi Biotherapeutics, Inc. (CLDI) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

CLDI

$0.77

−$0.00 (−0.26%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CLDI with… →

CLDI Key Statistics

As of Oct 21, 2026
Trading
Open
$0.76
Previous Close
$0.77
Day's Range
0.74–0.79
52-Week Range
0.87–27.84
Volume
63.66K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.33
Valuation
Market Cap
$3.31M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−36.47
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$19.91M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.68M
1-Year Return
−96.84%
Dividend and dates
Avg Volume
252.83K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CLDI closed at $0.77, −96.84% over 1 year.

Calidi Biotherapeutics, Inc. (CLDI) has a market capitalization of $3.31M.

In fiscal 2025, CLDI reported revenue of $0.00.

CLDI Stock Return by Calendar Year

Calidi Biotherapeutics, Inc. (CLDI) return since Nov 2021: what $10,000 became

1 year
$10,000 $316
−96.84%
5 years
$10,000 $0.41
−99.996%

If you had invested $10,000 in Calidi Biotherapeutics, Inc. (CLDI) at the close on November 1, 2021, the earliest close on record here, it would have been worth $0.41 at the close on October 21, 2026: −99.996% in total, −86.75% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−95.90%
2025−91.52%
2024−92.38%
2023−85.15%
2022+3.67%
2021 (partial year)+0.31%

As of October 21, 2026.

CLDI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$19.91M—
2024$0.00−$22.14M—
2023$0.00−$29.22M—
2022$45.00K−$25.43M−56,504.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.19M−$19.91M—
2024$0.00—−$21.60M−$22.14M—
2023$0.00$0.00−$26.11M−$29.22M—
2022$45.00K$31.00K−$23.13M−$25.43M−56,504.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Calidi Biotherapeutics, Inc. (CLDI) carries a market capitalisation of $3.31M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 29 employees.

CLDI last closed at $0.77 on October 21, 2026. That is $0.00 (−0.26%) against the previous close. The 52-week range on file runs from $0.87 to $27.84.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $19.91M. Trailing earnings per share are −36.47.

Across the 4 fiscal years on file, revenue moves from $45.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.33. Annualized volatility over the trailing 5 years is 132.94%. The trailing one-year total return is −96.84%. Across 5 years the annualized return works out at −86.75%.

Growth & Income

No dividend is on file for CLDI.

2026 is still running; the total return is −95.90% year to date. The strongest complete calendar year on file is 2022 at +3.67%; the weakest is 2024 at −92.38%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Calidi Biotherapeutics, Inc. (CLDI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Calidi Biotherapeutics, Inc. CLDI $3.31M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Calidi Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Visit website →